Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

PubWeight™: 2.17‹?› | Rank: Top 2%

🔗 View Article (PMID 15118763)

Published in Cell Death Differ on August 01, 2004


M Chawla-Sarkar1, S I Bae, F J Reu, B S Jacobs, D J Lindner, E C Borden

Author Affiliations

1: Center for Drug Discovery and Development, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

Articles citing this

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08

XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell (2007) 2.21

Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J (2005) 2.09

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood (2005) 2.06

Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. J Invest Dermatol (2013) 1.56

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther (2007) 1.49

E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia (2006) 1.49

Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol (2010) 1.41

Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia (2007) 1.33

Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32

Retracted Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem (2010) 1.29

Retracted Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J Biol Chem (2010) 1.24

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood (2005) 1.23

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med (2007) 1.21

Rotavirus nonstructural protein 1 suppresses virus-induced cellular apoptosis to facilitate viral growth by activating the cell survival pathways during early stages of infection. J Virol (2010) 1.18

Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res (2009) 1.13

X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol (2014) 1.08

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer (2009) 1.08

Retracted Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem (2010) 1.07

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res (2013) 1.06

mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res (2013) 1.04

Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02

A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer (2009) 1.02

Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther (2010) 1.02

c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One (2010) 1.01

Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99

Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci (2010) 0.98

Notch inhibits apoptosis by direct interference with XIAP ubiquitination and degradation. EMBO J (2007) 0.96

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96

Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One (2010) 0.96

Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. Free Radic Biol Med (2012) 0.95

Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood (2005) 0.94

Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res (2006) 0.94

Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol (2011) 0.94

Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget (2014) 0.93

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. Br J Cancer (2009) 0.91

Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. BMC Cancer (2010) 0.91

Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90

Sulforaphane prevents microcystin-LR-induced oxidative damage and apoptosis in BALB/c mice. Toxicol Appl Pharmacol (2011) 0.89

Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma (2013) 0.89

Rotaviral enterotoxin nonstructural protein 4 targets mitochondria for activation of apoptosis during infection. J Biol Chem (2012) 0.89

Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br J Pharmacol (2011) 0.89

Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol (2011) 0.89

Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (2012) 0.89

Valproate activates the Notch3/c-FLIP signaling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life? Bipolar Disord (2009) 0.88

Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death Dis (2014) 0.88

XIAP is not required for human tumor cell survival in the absence of an exogenous death signal. BMC Cancer (2010) 0.88

Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des (2011) 0.87

Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia (2013) 0.86

In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv (2009) 0.85

Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway. J Biol Chem (2013) 0.85

Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85

Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol (2010) 0.85

Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol (2008) 0.85

Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS One (2014) 0.84

Mind bomb 1 regulation of cFLIP interactions. Am J Physiol Cell Physiol (2009) 0.84

Active participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3). J Biol Chem (2011) 0.83

Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs. Int J Oncol (2016) 0.83

Rotavirus-encoded nonstructural protein 1 modulates cellular apoptotic machinery by targeting tumor suppressor protein p53. J Virol (2013) 0.82

Tumor necrosis factor (TNF) receptor-associated factor 7 is required for TNFα-induced Jun NH2-terminal kinase activation and promotes cell death by regulating polyubiquitination and lysosomal degradation of c-FLIP protein. J Biol Chem (2012) 0.81

Identification of cellular calcium binding protein calmodulin as a regulator of rotavirus A infection during comparative proteomic study. PLoS One (2013) 0.81

Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis. Cancer Cell Int (2011) 0.81

The Membrane Steps of Bacterial Cell Wall Synthesis as Antibiotic Targets. Antibiotics (Basel) (2016) 0.80

Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine Growth Factor Rev (2007) 0.80

Solamargine triggers cellular necrosis selectively in different types of human melanoma cancer cells through extrinsic lysosomal mitochondrial death pathway. Cancer Cell Int (2016) 0.79

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis (2014) 0.79

Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA. Int J Cancer (2010) 0.79

1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma. Biochem Pharmacol (2012) 0.79

Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Genes Nutr (2011) 0.79

Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1. Infect Immun (2010) 0.79

Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis. Nucleic Acid Ther (2013) 0.78

Vitamin E succinate induces apoptosis via the PI3K/AKT signaling pathways in EC109 esophageal cancer cells. Mol Med Rep (2016) 0.77

DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer Biol Ther (2014) 0.77

Expression of αB-crystallin overrides the anti-apoptotic activity of XIAP. Neuro Oncol (2012) 0.77

Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin. Exp Mol Med (2009) 0.77

Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells. PLoS One (2016) 0.76

5,7-Dihydroxyflavone Enhances the Apoptosis-Inducing Potential of TRAIL in Human Tumor Cells via Regulation of Apoptosis-Related Proteins. Evid Based Complement Alternat Med (2013) 0.76

Ethanolic extract of Thevetia peruviana flowers enhances TNF-α and TRAIL-induced apoptosis of human cervical cancer cells via intrinsic and extrinsic pathways. Oncol Lett (2017) 0.75

Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget (2016) 0.75

Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation. Cell Death Dis (2016) 0.75

The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. J Biol Chem (2016) 0.75

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget (2017) 0.75

Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis. Sci Rep (2016) 0.75

Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Mar Drugs (2015) 0.75

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther (2012) 0.75

The long noncoding RNA XIAP-AS1 promotes XIAP transcription by XIAP-AS1 interacting with Sp1 in gastric cancer cells. PLoS One (2017) 0.75

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells. PLoS One (2017) 0.75

Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death Through its Carboxyterminal Domain. Am J Respir Crit Care Med (2017) 0.75

Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy (2016) 0.75

N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cells. Sci Rep (2017) 0.75

Articles by these authors

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73

IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology (2006) 2.75

Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45

Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem (2000) 2.08

Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07

Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem (2001) 2.07

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04

In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia (2013) 1.84

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78

Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74

Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73

Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70

Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56

Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50

A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42

Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42

Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41

Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38

The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34

Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33

Measurement of peroxisomal fatty acid beta-oxidation in cultured human skin fibroblasts. J Inherit Metab Dis (1995) 1.31

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene (2011) 1.30

Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25

Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20

A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20

Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16

An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14

Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14

Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13

Acute appendicitis in children: factors affecting morbidity. Am J Surg (1984) 1.12

Lower extremity amputation in diabetic patients. Diabetes (1970) 1.12

Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09

Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08

Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother (2000) 1.07

Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06

Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res (1997) 1.06

Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J Immunol (1978) 1.05

Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma. Oncogene (2009) 1.05

Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol (1996) 1.05

Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res (1992) 1.04

Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04

Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene (2007) 1.03

Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus. Nat New Biol (1971) 1.03

Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med (1992) 1.03

Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02

Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene (2006) 1.02

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02

Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid. Antimicrob Agents Chemother (1978) 1.01

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 0.99

The effect of interferon on the metabolism of LDLs. Arterioscler Thromb (1992) 0.98

Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity. J Interferon Res (1990) 0.98

Studies on the poxvirus Cotia. J Gen Virol (1980) 0.97

Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha. J Interferon Res (1985) 0.97

o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement. Cancer (1978) 0.97

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96

The polyoma virus T antigen interferes with interferon-inducible gene expression. Proc Natl Acad Sci U S A (1998) 0.96

Human astrocytes proliferate in response to tumor necrosis factor alpha. J Neuroimmunol (1990) 0.96

Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96

Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res (1989) 0.94

Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res (1997) 0.93

2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals. AIDS (1991) 0.93

An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod (1985) 0.93

Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest (1985) 0.93

Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs (1990) 0.92

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer (2011) 0.91

Interferons: biochemical, cell growth inhibitory, and immunological effects. Prog Hematol (1981) 0.91

The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein. J Immunol (1975) 0.91

Birth order and sex of sibling as determinants of mother-infant interaction. Child Dev (1976) 0.90

Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90

Interferons: rationale for clinical trials in neoplastic disease. Ann Intern Med (1979) 0.90

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene (2011) 0.89

Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. J Immunother Emphasis Tumor Immunol (1993) 0.89

Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer (1997) 0.88

Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid. Antimicrob Agents Chemother (1979) 0.87

GRIM-19 inhibits v-Src-induced cell motility by interfering with cytoskeletal restructuring. Oncogene (2009) 0.87

Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. Clin Exp Immunol (1987) 0.87

The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci U S A (1997) 0.87

Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther (1997) 0.87

Tamoxifen enhances interferon-regulated gene expression in breast cancer cells. Mol Cell Biochem (1997) 0.87

Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines. J Urol (1991) 0.87

Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res (1989) 0.87

Microsatellite instability in the adenoma-carcinoma sequence of the stomach. Lab Invest (2000) 0.86

Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells. J Immunol (1984) 0.86

Comparison of agar and agarose preparations for mengovirus plaque formation. Appl Microbiol (1970) 0.86

In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. Cytokine (2000) 0.86

Effect of influenza A virus on leukocyte histamine release. J Allergy Clin Immunol (1983) 0.86